Corporate Collaborations: Scientists Can Face Publishing Constraints

Confidentiality agreements. Threats of lawsuits. Last-minute withdrawals of scientific papers. Sudden dismissals. Gag orders. Conflicts of interest, actual and potential. Lack of support for embattled faculty members by university administrators. It's a tough world for life scientists in the modern academic laboratory. Largely as a result of expanding commercial interest in academic research, today's faculty members and postdocs face threats and choices unknown to their predecessors. The poten

Written byPeter Gwynn
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

Confidentiality agreements. Threats of lawsuits. Last-minute withdrawals of scientific papers. Sudden dismissals. Gag orders. Conflicts of interest, actual and potential. Lack of support for embattled faculty members by university administrators. It's a tough world for life scientists in the modern academic laboratory. Largely as a result of expanding commercial interest in academic research, today's faculty members and postdocs face threats and choices unknown to their predecessors.

The potential dangers of academic-industrial links formed one focus of a recent colloquium at the Massachusetts Institute of Technology, titled "Secrecy in Science" and sponsored by the American Association for the Advancement of Science and M.I.T. Speakers at the event highlighted two specific types of pressure:

Speakers outlined three major instances of corporate pressure on life scientists to delay or cancel publication of research results. The best known is the case of David Kern, director of the Brown University Program in Occupational Medicine and ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies